The Centers for Medicare and Medicaid Services is rethinking a policy that limits millions of Americans’ access to one of the most effective resources for diagnosing and determining the course of treatment for Alzheimer’s disease.
With the finalization of a controversial draft policy, one federal agency dashed the hopes of millions of people living with Alzheimer’s and related dementias.
Every year, millions of people suffer from a brain disease, disorder or injury. Yet research on these conditions remains complex and sometimes frustrating.
Most Medicare beneficiaries could be blocked from accessing the first-of-its-kind therapy for Alzheimer’s disease, if a proposed rule goes into effect.
The latest update to the National Plan to Address Alzheimer’s Disease sets an ambitious goal: to prevent and effectively treat Alzheimer’s by 2025.
The number of Americans living with Alzheimer’s disease is growing – fast.
Access and awareness are one step closer now for people living with a movement disorder known as tardive dyskinesia.
For people living with Huntington’s disease, there may be help on the horizon as Congress looks to speed access to federal insurance coverage.
The term “nursing home” conjures up different images for different people. Some people picture active older adults playing bridge and doing water aerobics. Others have visions of wheelchair-bound, elderly who have more severe challenges.
There’s a public policy time bomb ticking that threatens to disrupt essential drug coverage for millions of vulnerable Americans.